Product Availability: In Stock (FedEx delivery within 2 business days).
Ordering: To place an order please use Add to Cart button (account not required).
Transfection Reagent for bEnd.3 Cell Line (Brain Endothelioma Cells, CRL-2299)
A nanoparticle-based liposome formulation
Transfection protocols provided for transfection of proteins, DNA, mRNA, siRNA, shRNA and microRNA
Transfection Enhancer reagent provided with the kit
Produce higher level of recombinant protein expression with minimal disruption of normal cell function
Generate physiologically relevant data you can trust
Effective for plasmid DNA/siRNA co-transfection
Easy-to-use transfection protocol with reproducible results
- Download bEnd-3 CRISPR/Cas9 transfection protocol: [PDF]
Download PowerPoint presentation for bEnd3 cells transfection kit: [PPT]
- UPC/GTIN/EAN: 860002089726
Brand: ALTOGEN®, developed and manufactured by Altogen Biosystems
Reagent exhibits at least 70% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems Transfection Protocol: [PDF]
Download MSDS: [PDF]
bEnd.3 Cell Line:
Stroke is a life-threatening disease that affects arteries in the brain and can be caused by the blockage of the arteries by a blood clot, resulting in seizures. bEnd.3 is a brain endothelial cell line taken from a mouse’s (Mus musculus) brain/cerebral cortex. As endothelial cells, they make up the interior surface of blood vessels and lymphatic vessels, which circulate blood. These cells form the structure that not only helps carry nutrients to the brain but also removes waste. The bEnd.3 cell line is used in a variety of molecular and cell biology research. Study of this cell could be useful for medical research related to the flow of blood, providing a test subject for ways to treat clots and congestion, which can cause seizures and other serious health effects. Altogen Biosystems offers an advanced liposome formulation bEnd-3 transfection reagent kit that provides high transfection efficiency with bEnd-3 cells and is a helpful tool for biomedical research applications related to the flow of blood and blood flow obstruction. bEnd3 is a cell line that was derived from the brain endothelium of a mouse. It is commonly used as a model system to study the blood-brain barrier (BBB), a specialized barrier that separates the brain from the circulatory system and regulates the exchange of substances between the two compartments. bEnd3 cells are adherent and grow in vitro as monolayer cultures. They form tight junctions and express various transporters and receptors that are characteristic of the BBB in vivo.
bEnd3 cells are often used in experiments to investigate the permeability of the BBB to various drugs and compounds, as well as to study the mechanisms of drug transport across the barrier. BEND.3 cells are also useful for studying the effects of neuroinflammation on the BBB. Inflammation can disrupt the tight junctions between endothelial cells and increase the permeability of the barrier, allowing harmful substances to enter the brain. BEND.3 cells have been used to investigate the signaling pathways involved in BBB disruption and to develop strategies for protecting the barrier during neuroinflammatory conditions. In summary, BEND.3 cells are a valuable cell line in biomedical research due to their ability to model the BBB and their utility in studying drug transport across the barrier, as well as the effects of neuroinflammation on BBB function.
Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the bEnd3 cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time RT-PCR for GAPD mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to untreated sample. Data are means ± SD (n=5).
Figure 2. Protein expression of GAPDH in bEnd-3 cells. DNA plasmid expressing GAPDH or siRNA targeting GAPDH were transfected into bEnd-3 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):
- Nature Biotechnology. 2011 29(4):341-5. Delivery of siRNA to the mouse brain by … Alvarez-Erviti et al [PDF]
- Jounal of Biological Chemistry. 2012 287(4):2907. Chaperoning of mutant p53 protein … Gogna et al [PDF]
- PLoS Pathogens. 2012 8(8) Uridine composition of the poly-U/UC tract of HCV RNA … Schnell et al [PDF]
- J Proteome Res. 2012(11) Retinal proteome analysis in a mouse model of oxygen-induced … Kim et al [PDF]
- J Transl Med. 2010 15;8:133. Prevention of hyperglycemia-induced myocardial apoptosis … Zhang et al [PDF]
Altogen Biosystems is a life sciences company that manufactures over 100 cell type specific and preoptimized transfection kits, electroporation buffers, and targeted in vivo delivery kits and reagents. Advanced formulation of reagents and optimized transfection protocols provide highly efficient intracellular delivery of biomolecules (proteins, DNA, mRNA, shRNA and siRNA, and small molecule compounds). Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Research Services:
Altogen Labs provides GLP compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6145)
- 1.5 ml (Catalog #6146)
- 1.5 ml CRISPR (Catalog #2113)
- 8.0 ml (Catalog #6147)